Evaluating the role of myeloperoxidase in cardiac surgery outcomes
Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.
This study is testing how a substance called myeloperoxidase affects recovery and complications in patients undergoing heart surgery like bypass grafting and valve repair.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | St. Petersburg State Pavlov Medical University Academic / other |
| Locations | 1 site (Saint-Petersburg, Non-US/Non-Canadian) |
| Trial ID | NCT03786965 on ClinicalTrials.gov |
What this trial studies
This study investigates the molecular biology of myocardial damage during cardiac surgery procedures. It aims to assess patient outcomes by measuring serum levels of myeloperoxidase and analyzing the morphology of the left atrial appendage, along with conducting genetic and cell biology analyses. The interventions include various types of coronary artery bypass grafting (CABG) and valve repair procedures. The goal is to better understand how these factors influence recovery and complications following surgery.
Who should consider this trial
Good fit: Ideal candidates include patients with ischemic heart disease or valve disease who require surgical intervention.
Not a fit: Patients who refuse to participate or do not have indications for surgery will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of outcomes and tailored treatment strategies for patients undergoing cardiac surgery.
How similar studies have performed: While the specific role of myeloperoxidase in this context may be novel, similar studies have shown promise in understanding biomarkers related to cardiac surgery outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ischemic heart disease with indications for operation * valve disease with indications for operation * ischemic heart disease combined with valve disease with indications for operation Exclusion Criteria: * patient refusal
Where this trial is running
Saint-Petersburg, Non-US/Non-Canadian
- Nikolai Bunenkov — Saint-Petersburg, Non-US/Non-Canadian, Russian Federation (Recruiting)
Study contacts
- Study coordinator: Alexander Nemkov, PhD
- Email: nemk_as@mail.ru
- Phone: +7-921-795-00-47
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.